

PRESS RELEASE
10 February 2023 13:00:00 CET

New Stockholm3 data accepted for presentation at the upcoming European Association of Urology meeting

Seven scientific abstracts, one thematic session and one plenary session related to Stockholm3 have been accepted for presentation at the upcoming 28th European Association of Urology (EAU) meeting that will be held March-10-13 in Milan, Italy.

The accepted presentations, outlined below, cover topics such as validation of Stockholm3 in new populations, experience from use of Stockholm3 in clinical practice and early mortality data from the original population based-Stockholm3 screening.

Abstract title	Presenting author, city	Session	Date /location
Prostate biopsies can be omitted in most patients with a positive Stockholm3-test and a negative prostate magnetic resonance imaging	M.N. Vigmostad, Stavanger (NO)	Abstract session 04	Friday March 10th, 15:15-16:45
External validation of Stockholm3 in a retrospective German clinical cohort	D. Tilki, Hamburg (DE)	Abstract session 04	Friday March 10th, 15:15-16:45
The Capio S:t Görans model for prostate cancer diagnosis using Stockholm3, magnetic resonance imaging and targeted biopsies	T. Palsdottir, Solna (SE)	Abstract session 04	Friday March 10th, 15:15-16:45
Update on current screening trials - STHLM3	T. Nordström, Stockholm (SE)	Plenary session, Yellow area, eURO Auditorium 1	Sunday March 12th, 8:00-10:30
Experiences from the Swedish population based organised prostate cancer testing programme	O. Bratt, Gothenburg (SE)	Thematic session, Yellow area, eURO Auditorium 1	Sunday March 12th, 13:45-15:15
The Stockholm3 prostate cancer screening trial (STHLM3): An interim analysis of mortality results after 6.5 years of follow-up	C. Micoli, Stockholm (SE)	Abstract session 48	Sunday March 12th, 17:30-19:00
Repeat prostate cancer screening using prostate-specific antigen, a multiplex blood-test and magnetic resonance imaging: 2nd screening round outcomes of STHLM3-MRI	T. Nordström, Stockholm (SE)	Abstract session 48	Sunday March 12th, 17:30-19:00

Prospective multicenter validation of the Stockholm-3 (STHLM3) test in a Middle European population	A. Elyan, Basel (CH)	Abstract session 48	Sunday March 12th, 17:30- 19:00
External validation of the Rotterdam Prostate Cancer Risk Calculator (RPCRC) and comparison to Stockholm3 for prostate cancer diagnosis in a Swedish population-based screening cohort	T. Palsdottir, Solna (SE)	Abstract session 48	Sunday March 12th, 17:30- 19:00

“The interest for Stockholm3 continues to grow in Europe and it is very encouraging to see external validation of the algorithm in countries outside Scandinavia, 5-year results after incorporating Stockholm3 into a clinical care system in the Stockholm community and six-year interim data evaluating prostate cancer mortality after one-time screening using Stockholm3. This further supports evidence for use of Stockholm3 as a reliable decision tool in selection of men for prostate cancer testing,” says Hari Vigneswaran MD, Director of Medical Affairs at A3P Biomedical.

The full abstracts are available today on the EAU23 virtual platform ([here](#)).

For additional information, please contact:

David Rosen, CEO
 Telephone: +46 10 1823325
 Email: david.rosen@a3p.com

About A3P Biomedical

A3P Biomedical's mission is to improve quality of life of men by radically increasing the precision in prostate cancer diagnostics. The company's lead product is **Stockholm3**, a blood test for early detection of aggressive prostate cancer. Stockholm3 has been developed by scientists at Karolinska Institutet and validated in clinical studies including more than 75,000 men. A3P Biomedical is headquartered in Stockholm, Sweden. For more information, please visit www.a3p.com.

About Stockholm3

Stockholm3 is a blood test that combines protein markers, genetic markers, clinical data, and a proprietary algorithm, to predict the risk of aggressive prostate cancer at an early stage. In clinical practice, Stockholm3 finds 100 percent more aggressive prostate cancers and reduces 50 percent of unnecessary biopsies compared to current practice with PSA (1).

Stockholm3 has been evaluated in clinical studies with more than 75,000 men. Data from the latest pivotal study, a randomized study including 12,750 men, was published in The Lancet Oncology in 2021. The study was also awarded the European Association of Urology (EAU) "Prostate Cancer Research Award 2022". Multiple additional studies have been published in high-impact journals, including a previous study with 58,000 men, published in The Lancet Oncology in 2015 (1).

Based on robust peer-reviewed clinical data, leading Nordic healthcare providers such as Capio S:t Görans Hospital in Sweden and Stavanger University Hospital in Norway have replaced PSA with Stockholm3. Region Värmland has introduced general screening for prostate cancer with the help of Stockholm3 for men in the age category 50-75. Patients benefit from a more precise test (increasing sensitivity and specificity) and healthcare providers can reduce the direct costs by 17 to 28 percent (1).

[\(1\) Publications, results and clinical validation.](#)

About prostate cancer

Prostate cancer is the second most common male cancer, and the fifth leading cause of cancer related death in men worldwide. According to WHO, 1.4 million men were diagnosed with prostate cancer and 375,000 deaths were reported in 2020. Incidence of prostate cancer is expected to increase by 70 percent until 2040, driven by an aging population.

Attachments

[New Stockholm3 data accepted for presentation at the upcoming European Association of Urology meeting](#)